PAS
KROS icon

Point72 Asia (Singapore)’s Keros Therapeutics KROS Stock Holding History

Point72 Asia (Singapore)’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$19.6K Buy
+1,236
New +$18.3K ﹤0.01% 716
2024
Q4 		– Sell
-3,844
Closed -$223K – 1050
2024
Q3 		$223K Buy
3,844
+1,033
+37% +$51K 0.04% 346
2024
Q2 		$128K Buy
+2,811
New +$151K 0.03% 416

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 Asia (Singapore)'s KROS Position: Q3 2025 in Review

Point72 Asia (Singapore) opened a new position in Keros Therapeutics (KROS) in Q3 2025: 1,236 shares worth $19.6K. The stake represents ﹤0.01% of the portfolio and ranks #716 among its holdings. This is a return to the name: Point72 Asia (Singapore) previously reported a position in KROS as recently as Q3 2024.

Point72 Asia (Singapore) first reported a position in KROS in Q2 2024 and has held it in 3 quarters since. The position peaked at $223K in Q3 2024. 155 funds tracked by Wall St. Rank hold KROS as of Q3 2025.

  • Point72 Asia (Singapore) held 1,236 shares of Keros Therapeutics worth $19.6K as of Q3 2025.
  • Keros Therapeutics was a new Point72 Asia (Singapore) position in Q3 2025.
  • Keros Therapeutics made up ﹤0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #716 holding.
  • Point72 Asia (Singapore) first reported a position in Keros Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Point72 Asia (Singapore)'s Keros Therapeutics position peaked at $223K in Q3 2024.
  • 155 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.